All In Biotech

Drug Trial Radar · NCT05724199

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 746 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

746

Actual

Start

Feb 21, 2023

Primary completion

Sep 15, 2024

Study completion Dec 4, 2024

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The coprimary objectives of the study are to: * evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™). * evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI).

Conditions

  • Atopic Dermatitis

Interventions

  • RocatinlimabDrug

    Subcutaneous (SC) injection

  • PlaceboOther

    SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24Time frame: Baseline and Week 24
  2. Number of Participants Who Achieved ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 24Time frame: Baseline and Week 24

Locations

234 sites in 26 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Medical Dermatology Specialists

    Phoenix, Arizona

  • Southwest Skin Specialists

    Phoenix, Arizona

  • US Dermatology Partners Sun City West

    Sun City West, Arizona

  • Arkansas Research Trials, LLC

    North Little Rock, Arkansas

  • Kern Research Inc

    Bakersfield, California

  • Keck Medicine of University of Southern California

    Los Angeles, California

  • Wallace Medical Group Inc

    Los Angeles, California

  • Antelope Valley Clinical Trials

    Palmdale, California

  • University of California at Davis Medical Center

    Sacramento, California

  • Kaiser Permanente South Sacramento Medical Center

    Sacramento, California

  • Acclaim Clinical Research

    San Diego, California

  • Kaiser Permanente Medical Center - Oakland

    San Francisco, California

  • Kaiser Permanente Medical Center - San Francisco

    San Francisco, California

  • Synergy Dermatology

    San Francisco, California

  • TrueBlue Clinical Research

    Tampa, Florida

  • Olympian Clinical Research - Tampa

    Tampa, Florida

  • Atlanta Dermatology, Vein and Research Center, PC

    Alpharetta, Georgia

  • Divine Dermatology and Aesthetics

    Atlanta, Georgia

  • NorthShore University HealthSystem

    Skokie, Illinois

  • DS Research

    Clarksville, Indiana

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Dermatology and Skin Cancer Center Leawood

    Leawood, Kansas

  • Industrial Medicine Associates Clinical Research Advanced Dermatology Care

    Monroe, Louisiana

  • Aesthetic and Dermatology Center

    Rockville, Maryland

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • Oakland Hills Dermatology

    Auburn Hills, Michigan

  • Somnos Clinical Research

    Lincoln, Nebraska

  • Skin Specialists PC

    Omaha, Nebraska

  • Vivida Dermatology

    Las Vegas, Nevada

  • Las Vegas Clinical Trials

    North Las Vegas, Nevada

  • Schweiger Dermatology Group, PC Research Division

    Hackensack, New Jersey

  • Albuquerque Clinical Trials Incorporated

    Albuquerque, New Mexico

  • Chear Center LLC

    The Bronx, New York

  • Accellacare of Wilmington

    Wilmington, North Carolina

  • Bexley Dermatology Research

    Bexley, Ohio

  • Velocity Clinical Research Inc

    Medford, Oregon

  • Paddington Testing Company Inc

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Health Concepts

    Rapid City, South Dakota

Showing 40 of 234 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.